Peter J McKinnon
Overview
Explore the profile of Peter J McKinnon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
6489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin X, Gupta D, Vaitsiankova A, Bhandari S, Leung K, Menolfi D, et al.
Mol Cell
. 2024 Oct;
84(20):3916-3931.e7.
PMID: 39383878
Poly (ADP-ribose) polymerase (PARP) 1 and 2 enzymatic inhibitors (PARPi) are promising cancer treatments. But recently, their use has been hindered by unexplained severe anemia and treatment-related leukemia. In addition...
2.
Zuckermann M, He C, Andrews J, Bagchi A, Sloan-Henry R, Bianski B, et al.
Mol Cancer
. 2024 Jun;
23(1):123.
PMID: 38849845
Background: Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase...
3.
Lin X, Gupta D, Vaitsiankova A, Bhandari S, Leung K, Menolfi D, et al.
bioRxiv
. 2024 Apr;
PMID: 38559022
Significance: This work shows that the hematological toxicities associated with PARP inhibitors stem not from impaired PARP1 or PARP2 enzymatic activity but rather from the presence of inactive PARP2 protein....
4.
Yang C, He Y, Wang Y, McKinnon P, Shahani V, Miller D, et al.
J Cell Mol Med
. 2023 Aug;
27(18):2770-2781.
PMID: 37593885
Glioblastoma (GBM) is an aggressive brain cancer with a poor prognosis. While surgical resection is the primary treatment, adjuvant temozolomide (TMZ) chemotherapy and radiotherapy only provide slight improvement in disease...
5.
Reuss D, Downing S, Camacho C, Wang Y, Piro R, Herold-Mende C, et al.
Neuropathol Appl Neurobiol
. 2023 Jun;
49(4):e12915.
PMID: 37296499
Aims: Nijmegen breakage syndrome (NBS) is a rare autosomal recessive disorder caused by hypomorphic mutations of NBS1. NBS1 is a member of the MRE11-RAD50-NBS1 (MRN) complex that binds to DNA...
6.
Dumitrache L, McKinnon P
Neuron
. 2022 Oct;
110(20):3217-3219.
PMID: 36265437
Abnormal activity of LINE-1 transposable elements has been associated with neurological disease. In this issue of Neuron, Takahashi et al. (2022) show that L1 hyperactivity occurs in the neurodegenerative syndrome...
7.
Aditi , McKinnon P
DNA Repair (Amst)
. 2022 Sep;
119:103406.
PMID: 36148701
Preservation of genomic integrity is crucial for nervous system development and function. DNA repair deficiency results in several human diseases that are characterized by both neurodegeneration and neuroinflammation. Recent research...
8.
Juuri E, Tikka P, Domanskyi A, Corfe I, Morita W, McKinnon P, et al.
Front Physiol
. 2022 May;
13:877565.
PMID: 35574464
Ptch receptors 1 and 2 mediate Hedgehog signaling pivotal for organ development and homeostasis. In contrast to embryonic lethal phenotype, mice display no effect on gross phenotype. In this brief...
9.
Kwak Y, Shaw T, Downing S, Tewari A, Jin H, Li Y, et al.
Sci Adv
. 2021 Dec;
7(51):eabg6363.
PMID: 34910524
The pathogenesis of inherited genome instability neurodegenerative syndromes remains largely unknown. Here, we report new disease-relevant murine models of genome instability–driven neurodegeneration involving disabled ATM and APTX that develop debilitating...
10.
Perez H, Abdallah M, Chavira J, Norris A, Egeland M, Vo K, et al.
Elife
. 2021 Nov;
10.
PMID: 34723800
Ataxia Telangiectasia (A-T) and Ataxia with Ocular Apraxia Type 1 (AOA1) are devastating neurological disorders caused by null mutations in the genome stability genes, A-T mutated () and Aprataxin (),...